Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabiola Atzeni

Showing results (281-290 of 395) with videos related to

Pageof 40
Sort By:
Internal Medicine Journal|October 30, 2019
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective studyAndreina Manfredi, Giulia Cassone, Federica Furini, et al.
Rheumatology (Oxford, England)|July 28, 2018
Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national registerGary J Macfarlane, Ross I R MacDonald, Ejaz Pathan, et al.
Autoimmunity Reviews|October 20, 2018
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian expertsEnnio Giulio Favalli, Andrea Becciolini, Roberto Caporali, et al.
International Immunopharmacology|December 3, 2017
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseasesCaterina Defendenti, Fabiola Atzeni, Sergio Malandrin, et al.
Plos One|August 4, 2012
Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesisGianfranco Ferraccioli, Barbara Tolusso, Francesca Bobbio-Pallavicini, et al.
Journal of Clinical Medicine|April 30, 2020
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance StudyMaria Antonietta Barbieri, Giuseppe Cicala, Paola Maria Cutroneo, et al.
The Journal of Rheumatology|April 3, 2012
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictorsFlorenzo Iannone, Elisa Gremese, Fabiola Atzeni, et al.
Annals of Laboratory Medicine|October 26, 2019
Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of ImmunogenicityMaurizio Benucci, Valentina Grossi, Mariangela Manfredi, et al.
Autoimmunity Reviews|September 27, 2008
Cardiovascular involvement in systemic autoimmune diseasesSimona Sitia, Fabiola Atzeni, Piercarlo Sarzi-Puttini, et al.
Journal of Clinical Medicine|February 11, 2023
Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory StudyVincenzo Venerito, Andreina Manfredi, Antonio Carletto, et al.
Pageof 40

Showing results (281-290 of 395) with videos related to

Sort By:
Pageof 40
Internal Medicine Journal|October 30, 2019
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective studyAndreina Manfredi, Giulia Cassone, Federica Furini, et al.
Rheumatology (Oxford, England)|July 28, 2018
Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national registerGary J Macfarlane, Ross I R MacDonald, Ejaz Pathan, et al.
Autoimmunity Reviews|October 20, 2018
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian expertsEnnio Giulio Favalli, Andrea Becciolini, Roberto Caporali, et al.
International Immunopharmacology|December 3, 2017
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseasesCaterina Defendenti, Fabiola Atzeni, Sergio Malandrin, et al.
Plos One|August 4, 2012
Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesisGianfranco Ferraccioli, Barbara Tolusso, Francesca Bobbio-Pallavicini, et al.
Journal of Clinical Medicine|April 30, 2020
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance StudyMaria Antonietta Barbieri, Giuseppe Cicala, Paola Maria Cutroneo, et al.
The Journal of Rheumatology|April 3, 2012
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictorsFlorenzo Iannone, Elisa Gremese, Fabiola Atzeni, et al.
Annals of Laboratory Medicine|October 26, 2019
Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of ImmunogenicityMaurizio Benucci, Valentina Grossi, Mariangela Manfredi, et al.
Autoimmunity Reviews|September 27, 2008
Cardiovascular involvement in systemic autoimmune diseasesSimona Sitia, Fabiola Atzeni, Piercarlo Sarzi-Puttini, et al.
Journal of Clinical Medicine|February 11, 2023
Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory StudyVincenzo Venerito, Andreina Manfredi, Antonio Carletto, et al.
Pageof 40